FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914833937> ?p ?o ?g. }

• W2914833937 endingPage "962" @default.
• W2914833937 startingPage "955" @default.
• W2914833937 abstract "¹⁷⁷Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy using PSMA-617 and PSMA-I&T ligands (¹⁷⁷Lu-PRLT) is an emerging treatment in metastatic castration-resistant prostate cancer (mCRPC). This retrospective study evaluates clinical outcomes of ¹⁷⁷Lu-PRLT in earlier and later phases of mCRPC grouped by previous taxane chemotherapy. <b>Methods:</b> A retrospective analysis was performed on 167 patients with mCRPC who underwent ¹⁷⁷Lu-PRLT between March 2013 and December 2016. Patients were classified as either taxane chemotherapy pretreated (T-pretreated) or naïve (T-naïve) depending on whether they had received taxane-based chemotherapy prior to ¹⁷⁷Lu-PRLT. Clinical outcome for T-pretreated and T-naïve patients was assessed by overall survival (OS), radiographic progression-free survival, and prostate-specific antigen (PSA) response rate. Univariate and multivariable analyses were performed for both T-pretreated and T-naïve patients to determine predictors of outcome. Toxicity was categorized by the Common Terminology Criteria for Adverse Events (version 4.03). <b>Results:</b> Of the 167 patients treated with ¹⁷⁷Lu-PRLT, 83 were T-pretreated and 84 were T-naïve. At baseline, T-pretreated patients had overall poorer performance status, a higher prevalence of bone metastases, higher PSA levels, lower hemoglobin levels, higher alkaline phosphatase (ALP) levels and had received more additional therapies compared with T-naïve patients. Median OS was 10.7 mo for T-pretreated patients and 27.1 mo for T-naïve patients. Median radiographic progression-free survival was 6.0 mo for T-pretreated patients and 8.8 mo for T-naïve patients. PSA response assessment was evaluable in 132 patients and seen in 25 of 62 (40%) T-pretreated patients and 40 of 70 (57%) T-naïve patients. Significant determinates of inferior OS in multivariable analysis for T-pretreated patients were poorer performance status, lower cumulative administered activity, and lower baseline hemoglobin. Higher baseline alkaline phosphatase was the only significant determinate of inferior OS in multivariable analysis for T-naïve patients. Overall ¹⁷⁷Lu-PRLT was safe, with minimal adverse effects evident during follow-up in both T-pretreated and T-naïve patients. <b>Conclusion:</b>¹⁷⁷Lu-PRLT is a promising therapy in mCRPC, with encouraging outcomes and minimal associated toxicity seen in both our T-naïve and heavily pretreated patient cohorts." @default.
• W2914833937 created "2019-02-21" @default.
• W2914833937 creator A5009383052 @default.
• W2914833937 creator A5023883867 @default.
• W2914833937 creator A5039341643 @default.
• W2914833937 creator A5048954546 @default.
• W2914833937 creator A5051446048 @default.
• W2914833937 creator A5076485367 @default.
• W2914833937 date "2019-01-25" @default.
• W2914833937 modified "2023-10-11" @default.
• W2914833937 title "Clinical Outcomes of ¹⁷⁷Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy" @default.
• W2914833937 cites W1546799663 @default.
• W2914833937 cites W1904433804 @default.
• W2914833937 cites W2080439368 @default.
• W2914833937 cites W2108549165 @default.
• W2914833937 cites W2110534364 @default.
• W2914833937 cites W2116066195 @default.
• W2914833937 cites W2120292596 @default.
• W2914833937 cites W2123526148 @default.
• W2914833937 cites W2137467802 @default.
• W2914833937 cites W2141454098 @default.
• W2914833937 cites W2148643283 @default.
• W2914833937 cites W2155679349 @default.
• W2914833937 cites W2166918329 @default.
• W2914833937 cites W2175765437 @default.
• W2914833937 cites W2303817381 @default.
• W2914833937 cites W2304896218 @default.
• W2914833937 cites W2471050799 @default.
• W2914833937 cites W2518199070 @default.
• W2914833937 cites W2520024435 @default.
• W2914833937 cites W2523333323 @default.
• W2914833937 cites W2525124727 @default.
• W2914833937 cites W2529703393 @default.
• W2914833937 cites W2532226140 @default.
• W2914833937 cites W2570618306 @default.
• W2914833937 cites W2591849683 @default.
• W2914833937 cites W2625296464 @default.
• W2914833937 cites W2740979023 @default.
• W2914833937 cites W2762824224 @default.
• W2914833937 cites W2799931007 @default.
• W2914833937 doi "https://doi.org/10.2967/jnumed.118.216820" @default.
• W2914833937 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30683770" @default.
• W2914833937 hasPublicationYear "2019" @default.
• W2914833937 type Work @default.
• W2914833937 sameAs 2914833937 @default.
• W2914833937 citedByCount "88" @default.
• W2914833937 countsByYear W29148339372019 @default.
• W2914833937 countsByYear W29148339372020 @default.
• W2914833937 countsByYear W29148339372021 @default.
• W2914833937 countsByYear W29148339372022 @default.
• W2914833937 countsByYear W29148339372023 @default.
• W2914833937 crossrefType "journal-article" @default.
• W2914833937 hasAuthorship W2914833937A5009383052 @default.
• W2914833937 hasAuthorship W2914833937A5023883867 @default.
• W2914833937 hasAuthorship W2914833937A5039341643 @default.
• W2914833937 hasAuthorship W2914833937A5048954546 @default.
• W2914833937 hasAuthorship W2914833937A5051446048 @default.
• W2914833937 hasAuthorship W2914833937A5076485367 @default.
• W2914833937 hasBestOaLocation W29148339371 @default.
• W2914833937 hasConcept C121608353 @default.
• W2914833937 hasConcept C126322002 @default.
• W2914833937 hasConcept C126894567 @default.
• W2914833937 hasConcept C143998085 @default.
• W2914833937 hasConcept C2776694085 @default.
• W2914833937 hasConcept C2777511904 @default.
• W2914833937 hasConcept C2777793932 @default.
• W2914833937 hasConcept C2780192828 @default.
• W2914833937 hasConcept C2781406297 @default.
• W2914833937 hasConcept C530470458 @default.
• W2914833937 hasConcept C71924100 @default.
• W2914833937 hasConcept C90924648 @default.
• W2914833937 hasConceptScore W2914833937C121608353 @default.
• W2914833937 hasConceptScore W2914833937C126322002 @default.
• W2914833937 hasConceptScore W2914833937C126894567 @default.
• W2914833937 hasConceptScore W2914833937C143998085 @default.
• W2914833937 hasConceptScore W2914833937C2776694085 @default.
• W2914833937 hasConceptScore W2914833937C2777511904 @default.
• W2914833937 hasConceptScore W2914833937C2777793932 @default.
• W2914833937 hasConceptScore W2914833937C2780192828 @default.
• W2914833937 hasConceptScore W2914833937C2781406297 @default.
• W2914833937 hasConceptScore W2914833937C530470458 @default.
• W2914833937 hasConceptScore W2914833937C71924100 @default.
• W2914833937 hasConceptScore W2914833937C90924648 @default.
• W2914833937 hasIssue "7" @default.
• W2914833937 hasLocation W29148339371 @default.
• W2914833937 hasLocation W29148339372 @default.
• W2914833937 hasOpenAccess W2914833937 @default.
• W2914833937 hasPrimaryLocation W29148339371 @default.
• W2914833937 hasRelatedWork W2006998169 @default.
• W2914833937 hasRelatedWork W2063125980 @default.
• W2914833937 hasRelatedWork W2292864322 @default.
• W2914833937 hasRelatedWork W2372740194 @default.
• W2914833937 hasRelatedWork W2414195533 @default.
• W2914833937 hasRelatedWork W4225163266 @default.
• W2914833937 hasRelatedWork W4367296998 @default.
• W2914833937 hasRelatedWork W4383058846 @default.
• W2914833937 hasRelatedWork W2467398483 @default.
• W2914833937 hasRelatedWork W4225328509 @default.

• next